CN104940652A - Traditional Chinese medicine composition for treating angioneurotic headache and preparation method - Google Patents
Traditional Chinese medicine composition for treating angioneurotic headache and preparation method Download PDFInfo
- Publication number
- CN104940652A CN104940652A CN201510315563.4A CN201510315563A CN104940652A CN 104940652 A CN104940652 A CN 104940652A CN 201510315563 A CN201510315563 A CN 201510315563A CN 104940652 A CN104940652 A CN 104940652A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine composition
- pain
- wind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating angioneurotic headache. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients in parts by weight: 8-12 parts of Szechuan lovage rhizome, 8-12 parts of gastrodiae tuber, 8-12 parts of radix saposhnikoviae, 8-12 parts of notopterygium root, 8-12 parts of angelica dahurica, 8-12 parts of myrrh, 8-12 parts of lumbricus and 8-12 parts of liquorice. A preparation method of the traditional Chinese medicine composition comprises the following steps: directly crushing the active pharmaceutical ingredients subjected to conventional treatment into fine powder; screening the fine powder with 100 meshes; after uniform mixing, packing the mixed powder into hard capsules to prepare capsules of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that Szechuan lovage rhizome is utilized for promoting qi to activate blood, dispelling wind and relieving pain, and removing blood stasis to ensure upward blood supply to the head and eyes, and serves as a monarch drug; gastrodiae tuber is utilized for calming liver wind, activating meridians to stop pain, and stabilizing dizziness through calming of liver wind; notopterygium root is utilized for relieving exterior syndrome to dispel cold, removing wind and dampness, and stopping pain; angelica dahurica is utilized for relieving exterior syndrome to dispel wind, and stopping pain; through the combination of gastrodiae tuber, notopterygium root and angelica dahurica, not only can wind caused by the liver yang be calmed, but also external wind can be dispelled, and qi circulation can be promoted to relieve pain; gastrodiae tuber, notopterygium root and angelica dahurica all serve as ministerial drugs; myrrh and lumbricus are utilized for promoting blood circulation to remove blood stasis, and stopping pain, and serves as an adjuvant; liquorice is utilized for harmonizing all the active pharmaceutical ingredients, and serves as a conductant drug; through the combination of the monarch drug, ministerial drugs and conductant drug, the effects of promoting blood circulation to remove blood stasis, dispelling wind and relieving pain can be realized, and the clinical therapeutic effect of treating angioneurotic headache is remarkable.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition and preparation method for the treatment of angioneurotic headache.
Background technology
Vascular headache is a kind of repeated relapsing headache caused due to vasomotor dysfunction, is common frdquently encountered disease clinically.Its outbreak position is often positioned at the inclined side of head, with side or bilateral temples paroxysmal pulsation jumping pain, distending pain or drilling pain for main feature, and sometimes can with blood vessel autonomic nervous dysfunction symptoms such as visual hallucination, hemianopsia, photophobia, nausea and vomiting.Because its outbreak is in periodicity, during morbidity, sharp ache is felt bad, and its outbreak is more and more in youngster, extremely large harmful effect is brought to the body and mind of patient, Epidemiological study shows, the migrainous prevalence of China is 985.2/10 ten thousand, and annual morbidity is 79.7/10 ten thousand.
Vascular headache belongs to the category such as the traditional Chinese medical science " wind syndrome of head ", " headache ", head is the mansion of clear sun, three YANG meridians arteries and veins is all walked to follow in women's head-ornaments, faint cloudy Liver Channel and governor vessel also can push up in mountain peak, the cloudy the vivid YANG QI of the vital organs of the human body all on give in head, therefore when six evil invasion and attack, or interior internal organs dysfunction of QI-blood in meridian and collateral, or the two combination of syndromes, all can cause headache.To fall ill the dirty person concerned with vascular headache, intentionally, liver,spleen,kidney also, and wherein dialectical especially common with treat from liver.The liver belonging to wood, property bar reaches, and main catharsis has the merit of store blood simultaneously, the function such as have harmonizing the functional activities of vital QI, emotion regulation, regulation and control blood and impel that menstruation is risen as scheduled.If liver catharsis too, then easily cause irritability liter and sent out prosperous, decline too late, occur the distending pain of upward invasion of liver-QI or excessive rising of liver-YANG, jumping pain, even headache is as split; And if the catharsis of liver is too late, then easily causing irritability and rise a deficiency, there is the distending pain in the head of stagnation of liver-QI blood stasis, twinge in hematogenous blockage, and woman menstruation is especially subject to this impact and falls ill, and is called " headache during menstruation "; Liver is the yang aspect of yin, and body is cloudy and with sun, if the deficiency of YIN-blood of liver, liver is lost and moistens foster and hepatic and renal YIN deficiency, and deficiency of kidney-YIN, can not contain wood, then excessive rising of liver-YANG, above disturbs key and cause distending pain in the head clearly.Present invention applicant finds vascular headache patient mostly with the situation of functional activity of QI being not smooth, blood-stasis internal-depression in clinical position, and during Headache attacks, many companions are dizzy, ophthalmic bloated pain, and conjunctival congestion, flushing etc. shows as the sign of qi depression to blood stasis; The present invention, through clinical practice for many years, sincerely abides by its pathogenesis, treatment is controlled with the method for blood circulation promoting and blood stasis dispelling, wind-expelling pain-stopping.
Summary of the invention
Technical problem to be solved by this invention is for the deficiencies in the prior art, and a kind of Chinese medicine composition for the treatment of angioneurotic headache is provided, this Chinese medicine composition name of product called after TIANXIONG Toutong Capsule, Chinese medicine composition blood circulation promoting and blood stasis dispelling of the present invention, wind-expelling pain-stopping, have remarkable mitigation to angioneurotic headache.
Another object of the present invention is to provide a kind of preparation method of above-mentioned Chinese medicine composition.
To achieve these goals, the present invention adopts following technical scheme:
Treat a Chinese medicine composition for angioneurotic headache, the crude drug comprising following weight portion is made: Rhizoma Chuanxiong 8-12 part, Rhizoma Gastrodiae 8-12 part, Radix Saposhnikoviae 8-12 part, Rhizoma Et Radix Notopterygii 8-12 part, Radix Angelicae Dahuricae 8-12 part, Myrrha 8-12 part, Pheretima 8-12 part, Radix Glycyrrhizae 8-12 part.
In the preferred technical scheme of the present invention, comprise Rhizoma Chuanxiong 10 parts, 10 parts, Rhizoma Gastrodiae, Radix Saposhnikoviae 10 parts, Rhizoma Et Radix Notopterygii 10 parts, the Radix Angelicae Dahuricae 10 parts, Myrrha 10 parts, Pheretima 10 parts, 10 parts, Radix Glycyrrhizae.
The present invention also provides a kind of preparation method of above-mentioned Chinese medicine composition, and above-mentioned each crude drug is directly ground into fine powder after conventional treatment, crosses 100 mesh sieves, obtains brown powder Chinese medicine composition after mixing.
Described crude drug is through conventional treatment, and that refer to necessity that crude drug is recorded according to " Chinese Pharmacopoeia " (2010) reference book, conventional processing procedure processes.
In preferred version of the present invention, further by described Chinese medicine composition process loading hard capsule routinely, make capsule.
Capsule of the present invention, specification is 0.4g/ every.
The instructions of taking of Chinese medicine composition of the present invention is:
One people 2 times on the one, each 3 ~ 5; A maximum consumption per day of being grown up is 4g/d, 14d is 1 course for the treatment of.
In Traditional Chinese medicine composition formula of the present invention, Rhizoma Chuanxiong promoting flow of QI and blood, again can wind-expelling pain-stopping, the up head, and the gas medicine in blood is monarch drug; Rhizoma Gastrodiae suppressing the hyperactive liver to relieve the wind syndrome, dredging collateral suppressing the hyperactive liver to relieve the wind syndrome, removing obstruction in the collateral to relieve pain, promote blood circulation network and pain relieving, put out liver-wind and fixed dizzy; Rhizoma Et Radix Notopterygii is induced sweat cold expelling, expelling wind and dampness, pain relieving; Radix Angelicae Dahuricae inducing diaphoresis to dispel wind, pain relieving; Three medicines are harmonious, and can put down the wind putting out liver-yang instituteization, loose exogenous wind of dispelling again, promoting the circulation of QI to relieve pain, are ministerial drug altogether; Myrrha, Pheretima blood circulation promoting and blood stasis dispelling, pain relieving is adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine; Monarch drug, ministerial drug, medicine is coordinated, function blood circulation promoting and blood stasis dispelling, wind-expelling pain-stopping, be mainly used in treating angioneurotic headache, clinical efficacy is remarkable.
The effect of the treatment angioneurotic headache of Chinese medicine composition of the present invention can with reference to following zoopery:
One, Chinese medicine composition of the present invention is to the protective effect of mice pain:
1, material
1.1, animal, environment and feedstuff:
Animal: SPF level KM mice, male and female half and half, body weight 18 ~ 22g, pleases laboratory animal by Jinan friend and breeds company limited and provide, credit number: SCXK (Shandong) 20140007; Animal divides cage by sex, 5, every cage, and cage tool is PC Merlon Mus box, cage tool specification 460 × 315 × 200mm (long × wide × high).
Raise environment: Shandong Province's Experimental Animal Center barrier environment Laboratory Animal Facility, credit number: SYXK (Shandong) 20140010.
Mice maintains feedstuff: Beijing HFK Bio-Technology Co., Ltd. provides, production licence number: SCXK (capital) 20090008.
1.2, medicine:
By reagent: pharmaceutical composition prepared by the embodiment of the present invention 1, a consumption per day of being grown up is 4g/d, according to people and Mice Body surface area scaling method, calculating mice dosage on the one is 4 × 0.0026 × 50g/kg=0.52g/kg, dosage three dosage component are not according to 4 of clinical equivalent amount, 2, 1 times, namely 2.08g/kg (experiment high dose group) is respectively, 1.04g/kg (in experiment dosage group), 0.52g/kg (experiment low dose group), administration volume is 20ml/kg, being mixed with containing crude drug amount concentration before use is respectively 0.104g/ml, 0.052g/ml, the decocting liquid of 0.026g/ml is for subsequent use.
Contrast medicine: (Yongning, Jinan Pharmacy stock Co., Ltd produces Aspirin Enteric-coated Tablets, lot number 20140202), the mice dosage 0.04g/kg (being equivalent to the equimultiple clinical application amount of being grown up) of Aspirin Enteric-coated Tablets matched group, administration volume is 20ml/kg, tablet is ground to form fine powder, be dissolved as suspension with distilled water, suspension concentration is 2mg/ml.
1.3, reagent and instrument:
Reagent: glacial acetic acid, Tianjin Bo Di Chemical Co., Ltd. product;
Instrument: hot-plate instrument.
2, method:
2.1, hot plate method detects different pharmaceutical to the impact of mice pain threshold:
KM mice being placed on the hot-plate instrument of 55 DEG C, putting into hot-plate instrument to occurring licking the pain threshold that metapedes required time (s) is this Mus with mice; Allly lick the metapedes time and be less than 10s or be greater than 30s or leaper and reject, by mice 100 qualified for screening, 5 groups are divided at random according to body weight, pain threshold equilibrium, i.e. blank group, Aspirin Enteric-coated Tablets matched group, in experiment high dose group, experiment, dosage group, experiment low dose group, often organize 20 mices.
Aspirin Enteric-coated Tablets matched group, each medicine 20ml/kg of mice respectively gavage respective concentration testing high, medium and low dosage group, continuous 7 days, after last administration 30,60,90,120,150min measures each group of mice pain threshold.According to surveyed pain threshold, after going out medication by following formulae discovery, percentage rate is improved in the threshold of pain of different time:
Percentage rate=[before (after medication the front average pain threshold of average pain threshold-medication)/medication average pain threshold] × 100% is improved in the threshold of pain.
2.2, writhing method detects different pharmaceutical to the impact of mice pain threshold:
By KM mice 100 (male and female half and half), be divided into 5 groups at random, i.e. blank group, Aspirin Enteric-coated Tablets matched group according to body weight, sex equilibrium, in experiment high dose group, experiment, dosage group, experiment low dose group, often organize 20 mices.
Aspirin Enteric-coated Tablets matched group, each medicine 20ml/kg of mice respectively gavage respective concentration testing high, medium and low dosage group, continuous 7 days, after last administration 30min, each group mouse peritoneal injects 0.6% acetum 0.1ml/10g (acetum prepared before use); Observe after injection acetum 5min and in 15min, occur the number of times (abdominal part shrinks indent, stretching, extension hind leg, buttocks are raised, crawling) of writhing response after record injection acetum, easing pain percentage rate by each medicine of following formulae discovery.
Analgesia percentage rate=[(matched group writhing response number of times-administration group writhing response number of times)/matched group writhing response number of times] × 100%.
2.3 statistical methods:
Application SPSS12 software carries out statistical analysis, and all data mean ± standard deviation represents, carries out t check analysis between measurement data group.
3, result:
3.1, hot plate method detects different pharmaceutical to the impact of mice pain threshold:
KM mice is placed on the hot-plate instrument of 55 DEG C, physical property thermostimulation is produced to mice and causes pain, after giving Aspirin Enteric-coated Tablets and each dosage Chinese medicine composition of the present invention, result is as shown in Table 1 and Table 2: the pain that three dosage groups of Chinese medicine composition of the present invention all can significantly suppress mice to cause physical property thermostimulation, improves mice pain threshold; Although after medication 30min, 60min, 90min, the effect of three dosage groups raising mice pain thresholds of Chinese medicine composition of the present invention is weaker than Aspirin Enteric-coated Tablets matched group; But, after medication 120min, the effect that experiment high dose group improves mice pain threshold is better than Aspirin Enteric-coated Tablets matched group, and after medication 240min, the effect that experiment high dose group improves mice pain threshold with dosage in experiment is all better than Aspirin Enteric-coated Tablets matched group; And, three dosage groups of Chinese medicine composition of the present invention, duration of efficacy is all long, along with the prolongation of medication experiment, analgesic activity strengthens thereupon, and pain threshold improves constantly, during 240min, still there is significant analgesic activity and analgesic activity is better than 120min time, and analgesic activity is weaker than 120min during Aspirin Enteric-coated Tablets matched group 240min, duration of efficacy is obviously not as three dosage groups of Chinese medicine composition of the present invention.
Table 1, different pharmaceutical are on the impact (n=20) of mice different time sections pain threshold
Note: compare " * " P<0.05 with blank group, " * * " P<0.01.
After table 2, the medication of each group mice, Different periods pain threshold improves percentage rate (n=20)
Note: compare " * " P<0.05 with Aspirin Enteric-coated Tablets matched group.
3.2, writhing method detects different pharmaceutical to the impact of mice pain threshold:
Mouse peritoneal injects 0.6% acetum, produces chemical stimulation and cause pain to mice; After giving Aspirin Enteric-coated Tablets and Chinese medicine composition of the present invention, result is as shown in table 3, and three dosage groups of Chinese medicine composition of the present invention have obvious analgesic activity to chemical stimulation pain, and wherein, the analgesic activity of experiment high dose group is the most remarkable; But, the analgesic activity of three dosage groups of Chinese medicine composition of the present invention is all more weak relative to Aspirin Enteric-coated Tablets matched group, because aspirin is the classical medication of chemical paroxysmal pain, this experiment embodies and just illustrates that this preparation has obvious pharmacodynamic action to the obvious analgesic activity of blank group, compares act on the routine also meeting pharmacological evaluation on the weak side with matched group.
Table 3, different pharmaceutical are on the impact (n=20) of each group of mice chemical irritation pain
Note: compare " * * " P<0.01 with blank group group.
Conclusion: the present invention adopts hot plate method in mice and writhing method two kinds of pain models, detect Chinese medicine composition analgesic activity of the present invention, hot plate method detects the display of analgesic activity result, Chinese medicine composition of the present invention is comparatively responsive to the analgesic effect of thermostimulation pain, mouse hot-plate can be significantly improved and stimulate pain caused pain threshold, and acting duration is longer reaches 4h, prove that this Chinese medicine composition has obvious analgesic activity to the pain that physical stimulation causes; Writhing method detects the display of analgesic activity result, and Chinese medicine composition of the present invention obviously can reduce mice because of the caused writhing number of times of acetic acid stimulation, proves that this Chinese medicine composition also has obvious analgesic activity to chemical induced pain.
Two, Chinese medicine composition of the present invention is on the impact of Migraine Rats modeling and hemorheology, cerebral blood flow:
1, material
1.1, animal, environment and feedstuff:
Animal: Wistar rat, male and female half and half, body weight 180 ~ 220g, pleases laboratory animal by Jinan friend and breeds company limited and provide, credit number: SCXK (Shandong) 20140007.
Raise environment: Shandong Province's Experimental Animal Center barrier environment Laboratory Animal Facility, credit number: SYXK (Shandong) 20140010.
Rat maintains feedstuff: Beijing HFK Bio-Technology Co., Ltd. provides, production licence number: SCXK (capital) 20090008.
1.2, medicine:
By reagent: pharmaceutical composition prepared by the embodiment of the present invention 1, a consumption per day of being grown up is 4g/d, according to people and rat body surface area scaling method, calculating rat dosage on the one is 4 × 0.018 × 5g/kg=0.36g/kg, dosage three dosage component are not according to 4 of clinical equivalent amount, 2, 1 times, namely 1.44g/kg (experiment high dose group) is respectively, 0.72g/kg (in experiment dosage group), 0.36g/kg (experiment low dose group), administration volume is 10ml/kg, being mixed with containing crude drug amount concentration before use is respectively 0.144g/ml, 0.072g/ml, the decocting liquid of 0.036g/ml is for subsequent use.
Contrast medicine: (Sanjiu Pharmaceutical Co., Ltd provides ZHENGTIAN WAN, lot number: 1406171); The mice dosage 1.5g/kg (being equivalent to adult's equimultiple clinical application amount) of ZHENGTIAN WAN matched group, administration volume is 10ml/kg, and ZHENGTIAN WAN is ground to form fine powder, is dissolved as suspension with distilled water, and suspension concentration is 0.15g/ml.
1.3, reagent and instrument:
Reagent: Dalian Trico Chemical Co., Ltd.'s product; Nitroglycerin: Shanxi KangBao Biology Products Co., Ltd's product; Urethanes (Ethylurethanm): upper seamount Pu Chemical Co., Ltd. product.
Instrument: laser doppler probe, automatic blood rheologic meter.
2, method:
2.1 grouping and modelings:
Wistar rat 60, male and female half and half, are divided into 6 groups at random by body weight, sex, and namely dosage group and experiment low dose group in blank group, model control group, ZHENGTIAN WAN matched group, experiment high dose group, experiment, often organize 10 rats.
Modeling method: the respective medicine of the rat difference gastric infusion respective concentration of dosage group and experiment low dose group in ZHENGTIAN WAN matched group, experiment high dose group, experiment, once a day, dosage is 10ml/kg, continuous 7 days; After last administration 30min, except blank group, all the other 5 groups of rats respectively subcutaneous injection nitroglycerin copy Migraine Rats model, and the concentration of nitroglycerin is 1mg/ml, and dosage is 10mg/kg.
2.2, observation index and method:
Blood flow test and index of correlation detect: after modeling 2h, the 20% Ethylurethanm intraperitoneal anesthesia of whole rat, cut off scalp expose pia mater encephali tissue with operating scissors, with laser doppler probe test rat cerebral tissue blood flow; Ventral aorta blood sampling 5ml, heparin sodium anticoagulant, automatic blood rheologic meter measures every hemorheology indexs such as whole blood viscosity, plasma viscosity, erythrocyte aggregation index, erythrocyte mechanical fragility, deformable index.
2.3, statistical method:
Application SPSS12 software carries out statistical analysis, and all data mean ± standard deviation represents, carries out t check analysis between measurement data group.
3, result:
Successive administration is after 7 days, and result is if table 4 is with shown in table 5: ZHENGTIAN WAN matched group, the height of testing high, medium and low dosage group mice are cut whole blood viscosity, lowly cut whole blood viscosity and plasma viscosity obvious decline compared with model control group, have significant difference; ZHENGTIAN WAN matched group, test cerebral blood volume obvious rising compared with model control group of high, medium and low dosage group mice, there is significant difference; The above results prompting modeling success.
ZHENGTIAN WAN and Chinese medicine composition of the present invention all can improve the low of mice and cut whole blood viscosity, and the improvement effect of ZHENGTIAN WAN is better than the present invention's three dosage groups; The height that ZHENGTIAN WAN and Chinese medicine composition of the present invention all can improve mice cuts whole blood viscosity, and experiment high dose group is improved the high successful cutting whole blood viscosity of mice and is better than ZHENGTIAN WAN; ZHENGTIAN WAN and Chinese medicine composition of the present invention all can improve the plasma viscosity of mice, and the successful that experiment high dose group and middle dosage group improve mice plasma viscosity is better than ZHENGTIAN WAN.ZHENGTIAN WAN and Chinese medicine composition of the present invention all can improve the cerebral blood flow of mice, and the successful that the high dose of Chinese medicine composition of the present invention improves mouse brain blood flow is better than ZHENGTIAN WAN.The above results shows, Chinese medicine composition of the present invention all has significant improvement result to rat model blood index and cerebral blood flow.
The change (n=10) of hemorheology of rat index respectively organized by table 4
Note: compare with model control group, " * " P<0.05, " * * " P<0.01.
Table 5 is group rat brain blood flow change (n=10) respectively
Note: compare with model control group, " * * " P<0.01.
Conclusion: Chinese medicine composition of the present invention can significantly improve the pain caused pain threshold of mice thermostimulation, and acting duration longer (can 4h be continued), possible analgesic activity is relevant with adjustment maincenter; Also obviously can reduce the number of times of mice caused writhing because acetic acid stimulates, and present certain dose-effect relationship.The Main Basis that nitroglycerin subcutaneous injection causes rat Nerve in Migraine Model is carotid artery vascular expansionary effect, nitroglycerin generates nitric oxide in vivo, bringing out experimental migraine by strong blood vessel dilating effect and neurotoxic effect, is one of headache medicine study model of extensive use; After traditional Chinese medicine composition for treating of the present invention, rat brain blood flow be improved significantly, whole blood is low to be cut, height is cut reduced viscosity and significantly declined, and this medicine may can reduce blood viscosity because of it to migrainous analgesic activity, improve cerebral blood flow, promote caused by cerebral blood circulation.The above results shows, Chinese medicine composition of the present invention has remarkable mitigation to angioneurotic headache, may be used for treating angioneurotic headache, and clinical practice has clear and definite pharmacodynamic action basis.
In addition, Chinese medicine composition of the present invention proves safe without toxic side effect through animal model acute toxicity test and long term toxicity test.
Detailed description of the invention
Below the detailed description of the invention of technical solution of the present invention is described in detail, but the present invention is not limited to following description content:
Embodiment 1:
Treat a Chinese medicine composition for angioneurotic headache, comprise crude drug: Rhizoma Chuanxiong 10g, Rhizoma Gastrodiae 10g, Radix Saposhnikoviae 10g, Rhizoma Et Radix Notopterygii 10g, Radix Angelicae Dahuricae 10g, Myrrha 10g, Pheretima 10g, Radix Glycyrrhizae 10g;
Preparation method is: above-mentioned each crude drug is directly ground into fine powder after the process of necessity, and sieve 100 mesh sieves, after mixing, conventionally load hard capsule, make capsule, this capsule called after TIANXIONG Toutong Capsule, every is 0.4g containing Chinese medicine composition.
Embodiment 2:
Treat a Chinese medicine composition for angioneurotic headache, comprise crude drug: Rhizoma Chuanxiong 8g, Rhizoma Gastrodiae 12g, Radix Saposhnikoviae 8g, Rhizoma Et Radix Notopterygii 12g, Radix Angelicae Dahuricae 8g, Myrrha 12g, Pheretima 8g, Radix Glycyrrhizae 12g;
Preparation method is: above-mentioned each crude drug is directly ground into fine powder after the process of necessity, and sieve 100 mesh sieves, after mixing, conventionally load hard capsule, make capsule, this capsule called after TIANXIONG Toutong Capsule, every is 0.4g containing Chinese medicine composition.
Embodiment 3:
Treat a Chinese medicine composition for angioneurotic headache, comprise crude drug: Rhizoma Chuanxiong 12g, Rhizoma Gastrodiae 8g, Radix Saposhnikoviae 12g, Rhizoma Et Radix Notopterygii 8g, Radix Angelicae Dahuricae 12g, Myrrha 8g, Pheretima 12g, Radix Glycyrrhizae 8g;
Preparation method is: above-mentioned each crude drug is directly ground into fine powder after the process of necessity, and sieve 100 mesh sieves, after mixing, conventionally load hard capsule, make capsule, this capsule called after TIANXIONG Toutong Capsule, every is 0.4g containing Chinese medicine composition.
Embodiment 4:
The routine clinical observation of TIANXIONG Toutong Capsule treatment angioneurotic headache 80 that embodiment 1 obtains:
1, Therapeutic Method:
1.1, patient's grouping:
Include case in and be in November, 2012 to 2013 my institute's Neurology Clinic and inpatient of year December, matched group and TIANXIONG Toutong Capsule treatment group is divided at random according to table of random number, each 40 examples: TIANXIONG Toutong Capsule treatment group, man 19 example, female 21 example, 25.2 years old mean age, course of disease 15d to 2.5 year, average 4.5 months; Matched group man 18 example, female 22 example, 24.7 years old mean age, the course of disease 1 month to 2 years, average 4.0 months.Two groups of physical data compare, and the equal not statistically significant of difference (P > 0.05), has comparability.
1.2, inclusive criteria:
Draft with reference to " new Chinese medicine guideline of clinical investigations ", coordinate TCD to check and assist diagnosis, all case TCD check that prompting has that intracranial vessel tensity increases, spasm, blood supply insufficiency or the reduction of cerebrovascular tensity, expansion etc.; The disease such as high cranium pressure, intracranial infection and intracranial spaceoccupying lesion simultaneously.
1.3, Therapeutic Method:
Matched group: take nimotop (Bayer HealthCare Co), 40mg/ time, 1 time/d, takes before sleeping.TIANXIONG Toutong Capsule treatment group patient gives embodiment 1 capsule for treating, 2 times on the one, each 3-5 grain, and maximum adult one consumption per day closes 4g/d.Two groups is all 1 course for the treatment of with 14d, follows up a case by regular visits to after treating 2 courses for the treatment of, 3 months statistics curative effects.
1.4, observation index:
Observe patient's TCM syndrome evaluation, times of headache, each headache persistent period etc.
Curative effect determinate standard: draft according to " new Chinese medicine guideline of clinical investigations ".Clinical recovery: headache and simultaneous phenomenon disappear.Effective: pain intensity and simultaneous phenomenon obviously alleviate, attack times, persistent period reduce more than 2/3.Effective: headache alleviates to some extent, outbreak extends interval time, and the persistent period reduces more than 1/3.Invalid: pain is without significant change or increase the weight of, and attack times increases, duration extension.
1.5, statistical analysis:
Adopt SPSS16.0 software kit statistics, measurement data represents with mean ± standard deviation, adopts t inspection; Ranked data adopt rank test, and enumeration data adopts χ
2inspection.P < 0.05 has statistical significance for difference.
2, result:
2.1 comparitive study:
The patient clinical treatment total effective rate of TIANXIONG Toutong Capsule treatment group is better than matched group, has obvious significant difference (P<0.05), as shown in table 6:
Table 6: two groups of patient's comparitive study
Note: two groups of comparitive study, " * " P<0.05.
2.2 liang of group TCM syndrome integral contrasts:
After two groups of treatments, Chinese medicine syndrome integral reduces before all comparatively treating, and difference has statistical significance (P < 0.05); Difference comparsion before and after treatment, TIANXIONG Toutong Capsule treatment group is better than matched group, difference has statistical significance (P < 0.05), illustrates that TIANXIONG Toutong Capsule treatment group is better than matched group improving in TCM symptom score, as shown in table 7:
Table 7 liang group TCM syndrome integral contrast
Note: compare with matched group, " * " P<0.05; " # " P<0.05 is compared before and after treatment.
2.3, two groups of panic attacks number of times and persistent period compare:
After two groups of treatments, panic attacks number of times and persistent period all comparatively treat front reduction, and difference has statistical significance (P < 0.05); All lower than matched group after the treatment of TIANXIONG Toutong Capsule treatment group, difference has statistical significance (P < 0.05), illustrate that TIANXIONG Toutong Capsule treatment group is improving the panic attacks number of times of patient and on the persistent period, equal melancholy is in matched group, as shown in table 8:
Table 8 liang group attack times and persistent period compare
Note: compare with matched group, " * " P<0.05; " # " P<0.05 is compared before and after treatment.
The above results shows, capsule for treating vascular headache determined curative effect of the present invention, and without obvious adverse reaction.
Above-mentioned example just for technical conceive of the present invention and technical characterstic are described, can not limit the scope of the invention with this.The equivalent transformation that all essence according to the present invention is done or modification, all should be encompassed within protection scope of the present invention.
Claims (4)
1. treat the Chinese medicine composition of angioneurotic headache for one kind, it is characterized in that, the crude drug comprising following weight portion is made: Rhizoma Chuanxiong 8-12 part, Rhizoma Gastrodiae 8-12 part, Radix Saposhnikoviae 8-12 part, Rhizoma Et Radix Notopterygii 8-12 part, Radix Angelicae Dahuricae 8-12 part, Myrrha 8-12 part, Pheretima 8-12 part, Radix Glycyrrhizae 8-12 part.
2. Chinese medicine composition according to claim 1, is characterized in that, comprises Rhizoma Chuanxiong 10 parts, 10 parts, Rhizoma Gastrodiae, Radix Saposhnikoviae 10 parts, Rhizoma Et Radix Notopterygii 10 parts, the Radix Angelicae Dahuricae 10 parts, Myrrha 10 parts, Pheretima 10 parts, 10 parts, Radix Glycyrrhizae.
3. a preparation method for the Chinese medicine composition described in any one of claim 1 ~ 2, is directly ground into fine powder by above-mentioned each crude drug after conventional treatment, crosses 100 mesh sieves, obtains Powdered Chinese medicine composition after mixing.
4. preparation method according to claim 3, is characterized in that, the Chinese medicine composition process loading hard capsule routinely will obtained further, makes capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510315563.4A CN104940652A (en) | 2015-06-10 | 2015-06-10 | Traditional Chinese medicine composition for treating angioneurotic headache and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510315563.4A CN104940652A (en) | 2015-06-10 | 2015-06-10 | Traditional Chinese medicine composition for treating angioneurotic headache and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104940652A true CN104940652A (en) | 2015-09-30 |
Family
ID=54156076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510315563.4A Pending CN104940652A (en) | 2015-06-10 | 2015-06-10 | Traditional Chinese medicine composition for treating angioneurotic headache and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104940652A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015135A2 (en) * | 2004-07-29 | 2006-02-09 | Howard Murad | Methods of managing the redness associated with a dermatological condition |
| CN104069175A (en) * | 2014-06-17 | 2014-10-01 | 王庚禹 | Extract used for preparing ligusticum wallichii tea modulator |
-
2015
- 2015-06-10 CN CN201510315563.4A patent/CN104940652A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015135A2 (en) * | 2004-07-29 | 2006-02-09 | Howard Murad | Methods of managing the redness associated with a dermatological condition |
| CN104069175A (en) * | 2014-06-17 | 2014-10-01 | 王庚禹 | Extract used for preparing ligusticum wallichii tea modulator |
Non-Patent Citations (2)
| Title |
|---|
| 字美慧: "川地汤治疗顽固性头痛的临床观察", 《中国医药指南》 * |
| 邹秋萍等: "川芎在头痛治疗中的应用", 《中国中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101347524B (en) | Chinese medicinal composition for treating depression and preparation thereof | |
| CN103285155A (en) | Traditional Chinese medicine composition for treating eczema and dermatitis | |
| CN102014931A (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN104042720B (en) | There is the Chinese medicine and application thereof of preventing and treating diabetes complicated depression | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN102462825B (en) | Compound traditional Chinese medicine for treating depression | |
| CN101095900B (en) | Sichuan chrysanthemum pain-relieving capsule and method for preparing the same | |
| CN101711809A (en) | Medicine composition for treating postpartum melancholia, preparation method and application | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| CN103638304B (en) | One treats migrainous Chinese medicine preparation of liver-Yang sthenia type and preparation method thereof | |
| CN105395600A (en) | Application of cyclocarya paliurus extract in preparing medicine for treating cardiovascular and cerebrovascular diseases | |
| CN104940652A (en) | Traditional Chinese medicine composition for treating angioneurotic headache and preparation method | |
| CN103239494B (en) | Nasal spray composition for treating migraine and preparation method thereof | |
| CN102641480B (en) | Traditional Chinese medicine composite used for treating microcirculation disturbance and preparation method thereof | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN110680880A (en) | Traditional Chinese medicine composition for treating liver-yang hyperactivity type insomnia and application thereof | |
| CN104352973A (en) | Chinese patent medicine for postpartum depression | |
| CN104435437B (en) | A kind ofly treat Chinese medicine of the concurrent glossopharyngeal neuralgia of trigeminal neuralgia and preparation method thereof | |
| CN104740210B (en) | A kind of Chinese medicine and preparation method for the treatment of qi stagnation and blood stasis type craniocerebral trauma syndrome | |
| CN108379367A (en) | Pure Chinese medicine drug of drug rehabilitation and preparation method thereof | |
| CN108567753A (en) | All beam dripping pill and its preparation process | |
| CN102813888A (en) | Chinese herbal composition for treating epilepsy | |
| CN104491687A (en) | Traditional Chinese medicine capsules for treating depression and preparation method thereof | |
| CN104383441A (en) | Method for preparing Chinese patent medicine for treating postpartum depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150930 |